Isofol Medical AB (publ) (STO:ISOFOL)
| Market Cap | 317.29M +63.2% |
| Revenue (ttm) | n/a |
| Net Income | -55.56M |
| EPS | -0.19 |
| Shares Out | 320.49M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 420,911 |
| Open | 0.9600 |
| Previous Close | 0.9550 |
| Day's Range | 0.9090 - 0.9950 |
| 52-Week Range | 0.5515 - 1.6800 |
| Beta | 1.29 |
| Analysts | n/a |
| Price Target | 3.63 (+266.16%) |
| Earnings Date | Nov 12, 2026 |
About Isofol Medical AB
Isofol Medical AB (publ) operates as a clinical stage biotech company. It develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. The company was incorporated in 2008 and is based in Gothenburg, Sweden. [Read more]
Financial Performance
Financial StatementsAnalyst Summary
The average 12-month stock price target for ISOFOL is krĀ 3.63, which is an increase of 266.16% from the latest price.
News
Isofol Medical AB Quarterly report: Q3 2026
Isofol Medical AB has published its Q3 2026 quarterly earnings report on November 12, 2026.
Isofol Medical AB Transcript: BioStock Life Science Summit 2026
Arfolitixorin is advancing through Phase Ib dose escalation, with no dose-limiting toxicities reported and interim tumor shrinkage in all treated patients. Phase II is planned to compare two doses with standard care, while the U.S. colorectal cancer opportunity was estimated at $1 billion in potential gross sales.
Isofol Medical AB Transcript: Investing in Life Science 2026
Arfolitixorin, a next-generation folate, is being developed to address the high unmet need in metastatic colorectal cancer, with promising early clinical results and a large commercial opportunity. Ongoing trials are expanding across multiple countries, and market research supports strong pricing potential if efficacy is demonstrated.
Isofol Medical AB Quarterly report: Q2 2026
Isofol Medical AB has published its Q2 2026 quarterly earnings report on August 25, 2026.
Isofol Medical AB Quarterly report: Q1 2026
Isofol Medical AB has published its Q1 2026 quarterly earnings report on May 19, 2026.
Isofol Medical AB Slides: FY 2026
Isofol Medical AB has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 10, 2026.
Isofol Medical AB Slides: Corporate presentation
Isofol Medical AB has posted slides in relation to its latest quarterly earnings report, which was published on March 9, 2026.
Isofol Medical AB Annual report: Q4 2025
Isofol Medical AB has published its Q4 2025 annual report on February 18, 2026.
Isofol Medical AB Quarterly report: Q4 2025
Isofol Medical AB has published its Q4 2025 quarterly earnings report on February 18, 2026.
Isofol Medical AB Slides: Corporate presentation
Isofol Medical AB has posted slides in relation to its latest quarterly earnings report, which was published on February 3, 2026.
Isofol Medical AB Slides: ABGSC Investor Days
Isofol Medical AB has posted slides in relation to its latest quarterly earnings report, which was published on December 4, 2025.